Analogues of leflunomide's primary metabolite, the malononitrilamides, prevent the development of graft-versus-host disease.
Schorlemmer
H U
HU
Research Laboratory Hoechst Marion Roussell, TA Rheumatology/Immunology, Wiesbaden, Germany.
Bartlett
R R
RR
Kurrle
R
R
D000480:Alkynes; D000818:Animals; D006086:Graft vs Host Disease / Q000517:prevention & control*; D007166:Immunosuppressive Agents / Q000494:pharmacology*; D007555:Isoxazoles; D008198:Lymph Nodes / Q000187:drug effects / Q000276:immunology / Q000473:pathology; D017710:Lymphocyte Transfusion; D051379:Mice; D008810:Mice, Inbred C57BL; D008811:Mice, Inbred DBA; D008815:Mice, Inbred Strains; D009570:Nitriles / Q000494:pharmacology*; D051381:Rats; D011914:Rats, Inbred BN; D011917:Rats, Inbred Lew; D014184:Transplantation, Homologous
D000480:Alkynes; D007166:Immunosuppressive Agents; D007555:Isoxazoles; D009570:Nitriles; C102911:X 910279; C115284:2-cyano-3-hydroxy-N-(4-(trifluoromethyl)phenyl)-2-hepten-6-ynamide